RESUMO
BACKGROUND: An association between herpes virus reactivations and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is accepted. We report six cases of DRESS with viral reactivation occurring within a single 1-month period. We attempted to find a common factor for these six cases and carried out clinical and virological examinations. Before and after this "epidemic", the mean number of cases of DRESS seen at the same centre was one per quarter, making the occurrence of six cases within a single month all the more remarkable and prompting us to seek an explanation. PATIENTS AND METHODS: All six patients had taken a partly causative medication from different drug classes three to six weeks prior to the start of symptoms and herpes virus was detected in the blood of all of these subjects at the time of DRESS onset (four reactivations and two primary infections), and one patient subsequently displayed herpetic meningoencephalitis 95 days after the initial episode, associated with recurrence of DRESS. DISCUSSION: There was no common denominator among these six DRESS patients in terms of either drug class or reactivation of a particular type of herpes virus, which raises the possibility of a single unidentified environmental agent. DRESS does not appear fully explainable in terms of a cellular response to drug antigens but seems rather to result from complex interactions between the drug-induced immune response, viral reactivation and antiviral immune response. Several investigators have reported sequential reactivation of herpes viruses in DRESS. A viral epidemic could thus cause a "DRESS epidemic" in patients on medication. CONCLUSION: These cases point to the possible existence of a shared initial environmental factor (infectious or not) that favours reactivation of herpes viruses and induces DRESS in patients on medication. Before and after this "DRESS epidemic", about one patient each quarter was admitted to hospital for DRESS.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/epidemiologia , Surtos de Doenças , Toxidermias/epidemiologia , Infecções por Vírus Epstein-Barr/epidemiologia , Síndrome Hipereosinofílica/epidemiologia , Infecções por Roseolovirus/epidemiologia , Estações do Ano , Injúria Renal Aguda/epidemiologia , Injúria Renal Aguda/etiologia , Adulto , Idoso , Alopurinol/efeitos adversos , Amoxicilina/efeitos adversos , Antibacterianos/efeitos adversos , Carbamazepina/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Citomegalovirus/fisiologia , Infecções por Citomegalovirus/complicações , Infecções por Citomegalovirus/epidemiologia , Toxidermias/etiologia , Infecções por Vírus Epstein-Barr/complicações , Feminino , França/epidemiologia , Herpesvirus Humano 4/fisiologia , Herpesvirus Humano 6/fisiologia , Herpesvirus Humano 7/fisiologia , Humanos , Síndrome Hipereosinofílica/induzido quimicamente , Síndrome Hipereosinofílica/etiologia , Imidazóis/efeitos adversos , Hospedeiro Imunocomprometido , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Infecções por Roseolovirus/complicações , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Ativação ViralAssuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Síndrome Hipereosinofílica/sangue , Síndrome Hipereosinofílica/induzido quimicamente , Artrite Reumatoide/sangue , Contagem de Células , Eosinófilos/patologia , Feminino , Humanos , Síndrome Hipereosinofílica/diagnóstico , Pessoa de Meia-Idade , Receptores de Interleucina-6/imunologia , Rituximab/uso terapêutico , Resultado do Tratamento , Suspensão de TratamentoRESUMO
Echinacea, believed by herbal practitioners to enhance the immune system, is one of the most widely used herbal supplements in the United States. Like most herbal products, it lacks strict FDA regulation and more information is needed about its potential adverse reactions. Here, we report the case of a patient with eosinophilia of unclear etiology whose condition resolved after cessation of this supplement. We feel this likely represents an IgE-mediated allergic process to echinacea.
Assuntos
Hipersensibilidade a Drogas/etiologia , Echinacea/efeitos adversos , Síndrome Hipereosinofílica/induzido quimicamente , Fitoterapia/efeitos adversos , Preparações de Plantas/efeitos adversos , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: While many cases of DRESS reaction to minocycline have been described, few of these involve doxycycline. CASE STUDY: A 59-year-old woman of African origin was repatriated after a journey to Ghana for hyperthermia with infiltrated maculopapular exanthema, facial oedema (no mucosal involvement) and polyadenopathy. Laboratory tests revealed hypereosinophilia, hepatic cytolysis and mononucleosis syndrome. Cutaneous histology was non-specific. The patient had been taking doxycycline as antimalarial prophylaxis for three weeks before the onset of symptoms. DRESS to doxycycline was diagnosed. Patch-tests with doxycycline three months later proved negative. The patient's HLA phenotype was A3/A30 and B39/B42. DISCUSSION: An intrinsic causal relationship with doxycycline was likely in this case (I3). Although patch-test sensitivity and specificity with doxycycline remains unknown in DRESS exploration, a negative result does not necessarily rule out the diagnosis. A number of cases of DRESS to doxycycline have been described recently, possibly as a result of more frequent prescription (malarial prophylaxis, acne). Subjects of African ethnicity or having specific HLA phenotypes are at higher risk of developing drug hypersensitivity. CONCLUSION: This patient is the third case of DRESS to doxycycline described in the literature. The originality of this case lies in the allergological investigation using patch-tests and HLA determination.
Assuntos
Antimaláricos/efeitos adversos , Doxiciclina/efeitos adversos , Toxidermias/etiologia , Febre/induzido quimicamente , Síndrome Hipereosinofílica/induzido quimicamente , Doenças Linfáticas/induzido quimicamente , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Feminino , Predisposição Genética para Doença , Gana/etnologia , Antígenos HLA/análise , Humanos , Pessoa de Meia-Idade , Testes do EmplastroRESUMO
A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilance database. Thirty-seven reports of eosinophilia induced by treatment with immune checkpoint inhibitors (ICIs) were included. The median [range] time to the absolute eosinophil count (AEC) peak was 15 [4â139] weeks. The median AEC was 2.7 [0.8â90.9] G/L. Eosinophil-related manifestations were reported in 21 of the 37 cases (57%). If administered, corticosteroids were always effective (n = 10 out of 10). Partial or complete remission of eosinophilia was obtained in some patients not treated with corticosteroids, after discontinuation (n = 12) or with continuation (n = 4) of the ICI. The AEC should be monitored in ICI-treated patients. If required by oncologic indications, continuation of ICI may be an option in asymptomatic hypereosinophilic patients, and in corticosteroid responders.
Assuntos
Antineoplásicos Imunológicos , Síndrome Hipereosinofílica , Bases de Dados Factuais , Humanos , Síndrome Hipereosinofílica/induzido quimicamente , Inibidores de Checkpoint Imunológico , FarmacovigilânciaRESUMO
Eosinophilia is uncommon in early rheumatoid arthritis (RA). The most frequent causes of hypereosinophilia during RA treatment are atopic eczema, allergy, helminth infection, haematological malignancy and drug-associated complications. The pathogenesis of this abnormality associated with anti-cytokine therapy is still unknown. We report the case of a young woman with RA and eosinophilia accompanied by systemic symptoms such as dyspnoea, fluid retention and eosinophilic vasculitis. An interesting observation was the persistence of eosinophilia during treatment with various biologics and its normalization after switching to the Janus kinase inhibitor baricitinib.
Assuntos
Artrite Reumatoide , Síndrome Hipereosinofílica , Inibidores de Janus Quinases , Artrite Reumatoide/tratamento farmacológico , Citocinas , Feminino , Humanos , Síndrome Hipereosinofílica/induzido quimicamente , Síndrome Hipereosinofílica/tratamento farmacológico , Inibidores de Janus Quinases/efeitos adversosRESUMO
INTRODUCTION: Drug rash with eosinophilia and systemic signs (DRESS) syndrome is defined by the triad of fever, dermatitis, and internal organ involvement, characteristically occurring with a delay of 3 to 8 weeks after the initiation of treatment with the associated drug. We describe a case of DRESS syndrome in a patient with multiple sclerosis (MS), characterized by a very high eosinophilia and cholestatic hepatitis. CASE SUMMARY: A 44-year-old white woman with primary progressive MS receiving a multidrug of PO baclofen 75 mg/d, PO piracetam 3 g/d, and IV mitoxantrone 10 mg administered once a month presented to the Multiple Sclerosis Center, University of Catania, Catania, Italy. Eight weeks after the introduction of the latter 2 drugs, the patient had clinical and histological signs of severe cholestatic syndrome followed by hypereosinophilia. All treatments were stopped on admission. Laboratory tests (serologic viral markers, autoantibody pattern antinuclear autoantibodies, antismooth muscle autoantibodies, antimitochondrial autoantibodies, antineutrophil-cytoplasmic autoantibodies, antiliver-kidney-microsomes), abdomen ultrasound, and magnetic resonance cholangiopancreatography did not reveal a cause of the cholestatic syndrome. A liver biopsy was performed because of the persistence of the clinical signs. A Naranjo rating of 4 suggested that mitoxantrone was possibly associated with the occurrence of DRESS. Six months after the first symptoms of DRESS appeared, laboratory tests were normal. Although there are few diagnostic methods for confirming an adverse drug hypersensitivity reaction, a skin prick test suggested a marked positivity for mitoxantrone at all concentrations (100%, 50%, 10%). During the first 72 hours, reaction was characterized by skin edema, erythema, and itchiness in the site of inoculation of the drug. The local reaction started to regress after 72 hours, with a complete restitution ad integrum in 6 days. A blue discoloration of skin remained for an additional 13 days. CONCLUSION: We report a case of DRESS syndrome possibly associated with mitoxantrone in a patient with MS.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/etiologia , Colestase/induzido quimicamente , Hipersensibilidade a Drogas/etiologia , Síndrome Hipereosinofílica/induzido quimicamente , Fatores Imunológicos/efeitos adversos , Mitoxantrona/efeitos adversos , Administração Oral , Adulto , Baclofeno/administração & dosagem , Biópsia , Doença Hepática Induzida por Substâncias e Drogas/patologia , Colestase/patologia , Hipersensibilidade a Drogas/patologia , Quimioterapia Combinada , Feminino , Humanos , Síndrome Hipereosinofílica/patologia , Fatores Imunológicos/administração & dosagem , Testes Intradérmicos , Mitoxantrona/administração & dosagem , Esclerose Múltipla , Piracetam/administração & dosagemRESUMO
Hypereosinophilic syndrome (HES) was diagnosed in December 2000 in a 43-year-old man on the basis of persistent eosinophilia (11.7 x 10(9)/L) and a normal karyotype of the bone marrow cells. He had developed intra-abdominal non-Hodgkin's lymphoma and in 1992 had received 3 courses of combination chemotherapy with doxorubicin (Adriamycin), cyclophosphamide, vincristine, methotrexate, bleomycin, and prednisolone. The patient was orally given prednisolone (10 mg/day) and cyclophosphamide (50 mg/day) as HES treatment without a subsequent improvement of the eosinophilia. In May 2003, anemia (hemoglobin, 7.9 g/dL) and thrombocytopenia (65 x 10(9)/L) manifested with progressive eosinophilia (21.0 x 10(9)/L) and a small number of blasts. The patient became febrile and was admitted in July 2003. Cytogenetic reexamination of the bone marrow cells disclosed the deletion of 4q12, indicating the presence of a fusion of the Fip1-like 1 (FIP1L1) gene to the plateletderived growth factor receptor alpha (PDGFRalpha) gene and consequently the clonal nature of his hematopoietic cells. DNA sequence analysis demonstrated that the breakpoints of the FIP1L1 and PDGFRalpha genes were present in exon 9 and exon 12, respectively. Treatment with imatinib mesylate (300 mg/day) promptly brought about complete remission. Although a number of similar eosinophilic cases have been reported, our patient may be the first such patient with a history of chemotherapy.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Síndrome Hipereosinofílica/etiologia , Proteínas de Fusão Oncogênica/genética , Receptor alfa de Fator de Crescimento Derivado de Plaquetas/genética , Fatores de Poliadenilação e Clivagem de mRNA/genética , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Benzamidas , Doença Crônica , Humanos , Síndrome Hipereosinofílica/induzido quimicamente , Síndrome Hipereosinofílica/tratamento farmacológico , Síndrome Hipereosinofílica/genética , Mesilato de Imatinib , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/tratamento farmacológico , Masculino , Dados de Sequência Molecular , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Análise de Sequência de DNARESUMO
A 92-year-old man with a history of bronchial asthma and allergic rhinitis received antibiotics for sepsis by methicillin-resistant Staphylococcus aureus and multidrug-resistant Enterococcus gallinarum. During the antibiotics treatment, skin eruptions, liver dysfunction, and hypereosinophilia developed, followed by dyspnea, congestive heart failure, electrocardiographic abnormalities, and diffuse mild myocardial hypokinesis. After the discontinuation of the antibiotics and the administration of steroid, skin eruptions, liver dysfunction, and hypereosinophilia improved parallel with the improvement of the congestive heart failure. Vancomycin hydrochloride and teicoplanin were suspected as the causative drugs on the basis of the treatment course. Although congestive heart failure is rare in the case of drug-induced hypereosinophilia, it is one of life-threatening complications. We describe herein a case of congestive heart failure associated with hypereosinophilia developed during antibiotics treatment, successfully treated with steroid after the discontinuation of the causative drug.
Assuntos
Antibacterianos/efeitos adversos , Insuficiência Cardíaca/induzido quimicamente , Síndrome Hipereosinofílica/induzido quimicamente , Sepse/tratamento farmacológico , Teicoplanina/efeitos adversos , Vancomicina/efeitos adversos , Idoso de 80 Anos ou mais , Resistência a Múltiplos Medicamentos , Quimioterapia Combinada , Enterococcus , Infecções por Bactérias Gram-Positivas , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Masculino , Resistência a Meticilina , Metilprednisolona/uso terapêutico , Sepse/microbiologia , Infecções Estafilocócicas , Resultado do TratamentoRESUMO
Hypereosinophilic syndrome represents a rare cause for cerebral infarctions and inflammatory neurological disorders. Various possible pathogenic mechanisms for cerebral infarctions have already been discussed. Complex mechanisms including a local hypercoagulability by eosinophilic granules as well as a direct damage to endothelial cells, leading to alterations of the microcirculation seem to be involved. The changing pattern of heroin use to inhalation/sniffing leading to an increasing abuse may cause a rise in the prevalence of Heroin induced eosinophilia, as it has been reported in a case of eosinophilic pneumonia associated with heroin inhalation. To our knowledge, the present case report displays the first description of stroke in the setting of heroin induced hypereosinophilia. Thus, besides usual vasoconstriction, HES should be considered in drug-induced cerebral infarctions.
Assuntos
Infarto Cerebral/etiologia , Heroína/efeitos adversos , Síndrome Hipereosinofílica/induzido quimicamente , Síndrome Hipereosinofílica/complicações , Adulto , Infarto Cerebral/diagnóstico , Humanos , Imageamento por Ressonância Magnética , MasculinoRESUMO
It has been reported that hypereosinophilic syndrome may be induced by antituberculosis drugs. We herein report the case of a 43-year-old man who had been on antituberculosis drugs for two months to treat tuberculous meningitis. During therapy, he suffered from drug rash with eosinophilia and systemic symptoms (DRESS) presenting as acute eosinophilic myocarditis, as confirmed on a histopathologic examination. According to the patient's medication history, clinical features and accessory examination findings, the eosinophilic myocarditis was thought to be possibly induced by isoniazid. Although further investigations are needed to confirm causality, isoniazid may be added to the list of drugs with the potential to cause DRESS syndrome.
Assuntos
Antituberculosos/efeitos adversos , Toxidermias/patologia , Síndrome Hipereosinofílica/induzido quimicamente , Isoniazida/efeitos adversos , Miocardite/induzido quimicamente , Adulto , Antituberculosos/administração & dosagem , Toxidermias/etiologia , Exantema/induzido quimicamente , Humanos , Síndrome Hipereosinofílica/patologia , Isoniazida/administração & dosagem , Masculino , Miocardite/patologia , Resultado do TratamentoAssuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Síndrome Hipereosinofílica/induzido quimicamente , Doenças Inflamatórias Intestinais/tratamento farmacológico , Mesalamina/efeitos adversos , Anti-Inflamatórios não Esteroides/uso terapêutico , Criança , Humanos , Masculino , Mesalamina/uso terapêuticoRESUMO
A 41-year-old man who had been taking pravastatin for two years developed hypersensitivity pneumonitis. The initial examination found intestinal pneumonitis and hypereosinophilia. The patient's syndromes gradually resolved with withdrawal of pravastatin. As HMG coenzyme A reductase inhibitors are commonly prescribed, any respiratory symptoms in this setting should be considered with special attention.
Assuntos
Alveolite Alérgica Extrínseca/induzido quimicamente , Anticolesterolemiantes/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Pravastatina/efeitos adversos , Adulto , Alveolite Alérgica Extrínseca/diagnóstico por imagem , Seguimentos , Humanos , Síndrome Hipereosinofílica/induzido quimicamente , Doença Iatrogênica , Masculino , Radiografia Torácica , Fatores de Tempo , Tomografia Computadorizada por Raios XRESUMO
Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine treatment. In parallel with the decrease in paroxetine dose, eosinophil count decreased and the related symptoms improved. Because it is sometimes difficult to distinguish between psychiatric symptoms such as panic attack and eosinophilia-related symptoms, frequent hematologic examination is required for patients treated with paroxetine.